Drug shows promise for posttransplant new-onset diabetes
from Renal & Urology News
In a small study, sitagliptin showed short-term efficacy and safety in the treatment of new-onset diabetes after renal transplantation. Dr. Thea Anine Strom Halden of Oslo University Hospital in Norway, and colleagues studied 19 long-term stable renal transplant recipients with new-onset diabetes after transplantation. The patients had a median age of 67 years. The investigators randomized patients to receive either sitagliptin 50-100 mg/day for four weeks followed by a sitagliptin-free period of four weeks or vice versa. Results showed that sitagliptin significantly increased first- and second-phase insulin secretion and lowered fasting and postprandial plasma glucose levels. The drug was well tolerated, and the researchers observed no effect on endothelial function and plasma markers of cardiovascular risk and no serious adverse events.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063